t
Beximco Pharmaceuticals PLC announced on 24 June 2026 that its Board of Directors, meeting on 23 June 2026, approved the Audited Financial Statements for the year ended 30 June 2025. The Board proposed a 47.5% cash dividend (Tk 4.75 per share) for the year ended 30 June 2025, with a record date of 2 August 2026. The 49th Annual General Meeting will be convened at the earliest practicable time, subject to obtaining necessary court permissions.
| Date | 24 Jun 2026 |
| Time | 07:05:00 |
| Category | Results |
| ID | 4602J |
24 June 2026
This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.
BEXIMCO PHARMACEUTICALS PLC.
Notification of Preliminary Results and Annual General Meeting
Beximco Pharmaceuticals PLC. ("Beximco Pharma" or "the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces information for shareholders of the Company that the Board of Directors decided at their meeting held on 23 June 2026. Please see further detail as follows:
|
1. |
To recommend the approval of the Financial Statements for the year ended 30 June 2025 |
The Audited Financial Statements for the year ended 30 June 2025 have been approved. The full accounts are expected to be announced later this week. |
|
2. |
Date & Time of 49th Annual General Meeting ("AGM") of the Company for the year ended 30 June 2025 |
The Annual General Meeting (AGM) will be convened at the earliest practicable time, subject to obtaining the necessary permission and condonation of delay from the Hon'ble High Court Division of the Supreme Court of Bangladesh. |
|
3. |
Proposed Dividend for the year ended 30 June, 2025 |
47.5% Cash Dividend (i.e. Tk 4.75 per Share) |
|
4. |
Record date |
2 August 2026 |
Preliminary results for the full year ended 30 June 2025 can be found in today's previous announcement titled: "Financial Results for the Periods from 1 January 2025 to 31 March 2026". The Company expects to publish its full accounts later this week. Once the full accounts have been published, the Company will seek to resume trading on AIM and further announcements will be made as appropriate.
For further information please visit www.beximcopharma.com or enquire to:
Beximco Pharma
S M Rabbur Reza, Chief Operating Officer
Tel: +880 2 58611001, Ext. 20111
Mohammad Ali Nawaz, Chief Financial Officer
Tel: +880 2 58611001, Ext. 20030
Mohammad Asad Ullah, FCS
Executive Director & Company Secretary
Tel: +880 2 41060531, Ext. 10140
SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Andrew Emmott
Tel: +44 (0)20 3368 3551 / 3555
SP Angel Corporate Finance LLP (Broker)
Matthew Johnson
Tel: +44 (0) 20 3470 0470
FTI Consulting
Simon Conway / Sam Purewal / Lucy Molloy
Tel: +44 (0)20 3727 1000
Notes to Editors
About Beximco Pharmaceuticals PLC.
Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.
Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 6,000 employees are driving the company towards achieving its aspiration to be among the most admired companies in the region.